2) Ahmad Masri MD @MasriAhmadMD from @OHSUCardio and Martha Grogan MD @MarthaGrogan1 #cardiologist at #MayoClinic provided a similar summary after #AHA2026, which is still available for 🆓CE/#CME credit at https://t.co/AsOSdcb2PO. We keep learning more! pic.twitter.com/ZrHtU7fLcn
— cardio-met (@cardiomet_CE) April 14, 2026
4a) Let’s start with a quick knowledge ✅. In #ATTRIBUTE_CM, what did early ⬆️ in serum #TTR with #acoramidis predict at 30 mos?
— cardio-met (@cardiomet_CE) April 14, 2026
a) No change in health status
b) Worse #KCCQ_OS
c) Better KCCQ_OS
d) Benefit only if #sTTR <20 mg/dL
4c) Across #ATTRibute_CM + OLE, early and continuous #acoramidis in #ATTR_CM was associated with:
— cardio-met (@cardiomet_CE) April 14, 2026
a) Worsening #KCCQ_OS and ⬆️ #NTproBNP
b) Stable status and ⬇️ #ACM/#CVM over ~54 mos
c) No difference vs placebo
d) More safety issues over time
5b) They assessed the least-squares mean Δ from baseline in KCCQ-OS score according to early ⬆️ in ΔsTTR at Day 28 by 5 & 10 mg/dL, in the #mITT population, and showed that early⬆️sTTR correlated to ⬆️ long-term health status in #ATTRCM as measured by KCCQ. pic.twitter.com/amKfLEP81O
— cardio-met (@cardiomet_CE) April 14, 2026
5d) Regardless of treatment group, patients with low #sTTR (<20 mg/dL) levels at day 28 had markedly worse (−18.4) KCCQ-OS scores at month 30 (p<0.0001).
— cardio-met (@cardiomet_CE) April 14, 2026
6a) @sarahcud et al presented an abstract along similar lines, assessing the long-term benefits with #acoramidis on #KCCQ_OS score vs serum #TTR levels at 54 mos in #ATTRIBUTE_CM trial plus its open label extension (#OLE). pic.twitter.com/x5eE1sdoca
— cardio-met (@cardiomet_CE) April 14, 2026
6c) Patients who transitioned from placebo to #acoramidis at Month 30 experienced stabilization of #KCCQ_OS scores along with increases in #sTTR levels, both of which were maintained through Month 54. pic.twitter.com/SCvM65Tavy
— cardio-met (@cardiomet_CE) April 14, 2026
7a) @cardiomet_ce faculty @Ron_Witteles presented a post-hoc analysis of the #ATTR_ACT study of #tafamidis looking at functional stability at 12mos & the subsequent impact on all-cause mortality (#ACM) and CV-related hospitalization (#CVH). pic.twitter.com/Kvf1srcT15
— cardio-met (@cardiomet_CE) April 14, 2026
7c) At Month 12, more pts on #tafamidis had #6MWD stability (64%) v pbo (53%). At 30mos, #ACM incidence of 11.5% for pts on tafamidis w/12mo 6MWD stability vs. 34.0% w/6MWD progression ➡️signif 73% ⬇️HR, p=0.0006).
— cardio-met (@cardiomet_CE) April 14, 2026
7e) Annual #CVH rates with placebo (0.79/year with 6MWD stability; 1.31/year with 6MWD progression) were higher vs. #tafamidis (0.71/year with 6MWD stability; 0.88/year with 6MWD progression).
— cardio-met (@cardiomet_CE) April 14, 2026
7g) . . . and was associated with lower subsequent #mortality and CV hospitalization, including in those with functional decline.
— cardio-met (@cardiomet_CE) April 14, 2026
8b) 1⃣making sure the diagnosis is correct by understanding the diagnostic algorithm
— cardio-met (@cardiomet_CE) April 14, 2026
2⃣proper acquisition & interpretation of nuclear cardiac #amyloid #scintigraphy (aka #PYP, #HMDP, #DPD)
3⃣always excluding AL and . . .
8d) BONUS: 3 huge mistakes in use of PYP/HMDP/DPD: 1) Not properly ruling out #AL amyloid 2) Not doing #SPECT to confirm #myocardial uptake 3) Not doing enough cardiac biopsies (when clinical suspicion persists or imaging findings are atypical) pic.twitter.com/DZIH5UjS63
— cardio-met (@cardiomet_CE) April 14, 2026
9b) This was a #LBCT at #ACC2026 and was simultaneously published in @JAMACardio. #Acoramidis was associated with significant reductions in #ACM and #CVM, and that observed treatment effect was consistent across subgroups: pic.twitter.com/lUdQwQngT9
— cardio-met (@cardiomet_CE) April 14, 2026
9d) No significant new safety signals associated with #acoramidis were identified. The published paper in @JAMACardio is at: 🔓https://t.co/AGubBq5WAq pic.twitter.com/lU21W3X3iF
— cardio-met (@cardiomet_CE) April 14, 2026
10b) Cardiac #amyloidosis leads to worsening #diastolic function. Here you see the baseline characteristics of pts according to their diastolic dysfunction grade, and the results that there was consistent benefit of #vutrisiran regardless of diastolic dysfunction stage: pic.twitter.com/21kT0R5v6J
— cardio-met (@cardiomet_CE) April 14, 2026
11b) Despite the progress in the #ATTRCM treatment space at the time of the survey, physicians & pts queried were generally not entirely satisfied with the treatments offered. pic.twitter.com/3adRW32iS0
— cardio-met (@cardiomet_CE) April 14, 2026
12) #ACC26 adds to a consistent story: early and sustained #TTR stabilization with #acoramidis improves patient-reported health status, preserves biomarkers/functional capacity, and reduces #ACM and #CVM over years—not just months—in #ATTR_CM.
— cardio-met (@cardiomet_CE) April 14, 2026
14) For clinicians, the mandate is clear: maintain a high index of suspicion, use nuclear #amyloid imaging correctly, always exclude AL, and start disease-modifying therapy early so our pts with #ATTR_CM can live longer and feel better. #Amyloid #FOAMed
— cardio-met (@cardiomet_CE) April 14, 2026
15) And so CONGRATULATIONS 🥳are in order for YOU 🫵. You can go NOW and claim 0.75hr 🆓CE/#CME credit at https://t.co/JrwOfahqrM ! Many thanks to our expert authors @MasriAhmadMD and @MarthaGrogan1. FOLLOW US for more #MedEd on diverse #cardiometabolic topics!
— cardio-met (@cardiomet_CE) April 14, 2026